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PolyploidyAbstract Background and purpose: Hydralazine (HDZ) is a cardiovascular drug that is widely
used to treat hypertension. The present study was done to assess the cytogenetic effects of HDZ
on Chinese hamster ovary (CHO) cells.
Materials and methods: Methylthiazol tetrazolium (MTT) assay was carried out to determine the
half maximal inhibitory concentration (IC50) of the drug. The IC50 value for HDZ was
243.3 ± 16.9 lg/ml. To investigate the clastogenic effects of the drug, chromatid breaks and poly-
ploidy in metaphases were analyzed. CHO cells were exposed to different concentrations of HDZ
(20 and 40 lg/ml) for 24 h. The experiments were carried out in the presence and absence of met-
abolic activation system (S9 mix; 1 ml S9 mix contained: 0.3 ml phosphate solutions, 0.2 ml KCl,
0.2 ml MgCl2, 0.1 ml S9 fraction, 0.1 ml G-6-P and 0.1 ml NADP), because HDZ is metabolized
in the liver. Mitomycin-C and sodium arsenite were used as positive controls.
Results: In the absence of S9 fraction, the level of chromatid breaks statistically increased
(P= 0.011) and mitotic index signiﬁcantly decreased (P< 0.001) in CHO cells treated with
HDZ. There was no signiﬁcant difference between treated and untreated CHO cells with HDZ
for the level of polyploidy (F= 0.05; df = 2, 6; P= 0.945). In the presence of S9 fraction, although
the mitotic index elevated, still there was a signiﬁcant difference between control and treated cells
(F= 50.53; df = 2, 6; P< 0.001). There was no signiﬁcant difference between 20 lg/ml of HDZ
(+S9) and untreated cells for frequency of chromatid breaks. However, at the 40 lg/ml concentra-
tion of HDZ (+S9), there was a signiﬁcant difference between treated and untreated cells.
Conclusion: HDZ have genotoxic effects on CHO cells in their non-toxic dose, but S9 mix addi-
tion decreased these effects.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Hydralazine (HDZ) is an antihypertensive drug used to treat
hypertension, congestive heart failure, myocardial infarction
and preeclampsia [1–5]. HDZ was found to create free radicals
[6–8]. It has been reported that HDZ has mutagenic effect in
bacterial test systems [9–12]. It is suggested that active oxygen
344 M. Sedigh-Ardekani, M. Saadatspecies generated by dihydralazine contribute to its mutagenic-
ity [11].
It has been shown that HDZ increases the risk of cancers in
mice and humans [13–15]. On the other hand, it has been
reported that HDZ has anticancer effect on some cancer cells
[16,17]. It should be noted that HDZ reactivated tumor sup-
pressor genes [18]. HDZ was found to decrease apoptosis
and free radical generation in both neurons and thymocytes
[19]. Taken together, it is very likely that HDZ has interaction
with DNA and chromosomes. The aim of the present study
was to assess the effect of HDZ on chromosomes of Chinese
hamster ovary (CHO) cells.2. Materials and methods
2.1. Chemicals
Hydralazine HCl (hydrapres, 20 mg) was obtained from
Rubio, nicotinamide adenine dinucleotide phosphate (NADP)
was obtained from Sigma, Glucose-6-phosphate from Fluka,
sodium arsenite (0.1 N) and mitomycine.Figure 1 Effect of hydralazine on cell growth of Chinese hamster
ovary (CHO) cell line for 24 h. The results are presented as percent
of inhibition of cell growth obtained by MTT assay. Data are
mean ± SD of triplicate experiments.2.2. Cell culture
In the present study, experiments were carried out using cul-
tured Chinese hamster ovary (CHO) cells. The CHO cells were
maintained in RPMI-1640 medium (from GIBCO) supple-
mented with 10% inactivated fetal calf serum (from GIBCO),
2 mM L-glutamine and with the addition of penicillin (100 U/
ml) and streptomycin (100 mg/ml).
This study was approved by the Shiraz University eth-
ics committee. This work is carried out in accordance with
the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving animal
experiments.
2.3. Methylthiazol tetrazolium (MTT) assay
Cells were seeded into 96-well plates at 2 · 104 cells/well in
100 ll complete medium. After the cells clung to plates, the
cells were treated with various concentrations of HDZ (25,
50, 100, 200, 500 and 1000 lg/ml) for 24 h. Final volume in
each well was 200 ll. Subsequently, the cell viability was mea-
sured by MTT dye reduction assay [20,21]. The formazan dye
was measured by ELISA reader. After obtaining the absorp-
tion, percentage inhibition of cell growth was calculated. The
IC50 is deﬁned as the cytotoxicity index that reduces the cell
number to 50% compared with untreated-control CHO cells.
2.4. Metabolic activation system
Liver S9 fraction was obtained from Wistar male rats induced
with phenobarbital. The livers from three rats were removed,
pooled and S9 fraction (10,00g) supernatant was prepared fol-
lowing the standard procedure. Immediately before use, a S9
mix (S9 fraction with cofactors) was prepared: 1 ml S9 mix
contained: 0.3 ml phosphate solutions, 0.2 ml KCl, 0.2 ml
MgCl2, 0.1 ml S9 fraction, 0.1 ml G-6-P and 0.1 ml NADP.
The S9 mix was added (50 ll) to the cultures.2.5. Chromosomal analysis
Chromosomal aberration assay was performed to investigate
the cytogenetic effects of HDZ (in the presence and/or absence
of S9 mix). The CHO cells were seeded at the density of
1.8 · 106 cells/ml in the volume of 10 ml. After 48 h, the cells
were treated with different doses of HDZ (20 and 40 lg/ml)
for 24 h. The cells were treated also with 20 and 40 lg/ml of
HDZ in the presence of 50 ll of S9 mix. After 6 h of incuba-
tion, the medium was changed and the cells were incubated
for 18 h. Mitomycin-C (0.06 lg/ml) and sodium arsenite
(1 lgM) were used as positive controls [22–25]. Chromosomes
were conventionally stained with Giemsa. In each slide, 100
metaphase spreads were analyzed in order to determine the
chromosomal aberrations. Chromosome aberrations were clas-
siﬁed to chromatid breaks and polyploidy. To determine the
mitotic index (percentage of cells in mitosis), 1000 cells in each
slide were observed.
2.6. Statistical analysis
All experiments (for determining either cytotoxicity or chro-
mosomal aberrations) were performed in triplicate for each
concentration. The level of the chromatid breaks, polyploidy,
and mitotic index are presented as mean ± standard deviation
(SD). The half maximal inhibitory concentration (IC50) is a
value indicating the concentration needed to inhibit cell prolif-
eration by half. Comparisons of the mean values of the studied
indices were done using one way analysis of variance
(ANOVA). We used Duncan test as a Post hoc test. Statistical
analysis was performed using SPSS statistical software pack-
age (version 11.5) for windows (SPSS Inc., Chicago, IL,
USA). A probability of P< 0.05 was considered statistically
signiﬁcant. All P-values were two-tailed.
3. Results
We analyzed the effect of HDZ on proliferation of CHO
cells using MTT assay (Fig. 1). The percent of cell growth inhi-
bition was increased as a function of HDZ concentration
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estimated to be 243.3 ± 16.9 lg/ml.
The effects of HDZ on chromosomal aberrations in treated
cells are shown in Table 1. In the positive control cells treated
with sodium arsenite and Mitomycin-C either chromatid
breaks or polyploidy increased and mitotic index decreased
compared with the untreated control cells (P< 0.001).
In the absence of S9 fraction, the level of chromatid breaks
statistically increased (F= 10.44; df = 2, 6; P= 0.011) and
mitotic index signiﬁcantly decreased (F= 68.58; df = 2, 6;
P=<0.001) in CHO cells treated with HDZ. There was no
signiﬁcant difference between treated and untreated CHO cells
with HDZ for level of polyploidy (F= 0.05; df = 2, 6;
P= 0.945).
In the presence of S9 fraction compared to the absence of
S9 fraction, the mitotic index elevated in treated CHO cells
with HDZ (Table 1). However, there was a signiﬁcant differ-
ence between control and treated cells (F= 50.53; df = 2,
6; P< 0.001). In the presence of S9 fraction, the level of chro-
matid breaks showed statistically signiﬁcant differences
between the experimental groups (F= 23.87; df = 2, 6;
P= 0.001). For frequency of chromatid breaks, there was
no signiﬁcant difference between 20 lg/ml of HDZ (+S9)
and untreated cells (P> 0.05). However, at the 40 lg/ml con-
centration of HDZ, there was a signiﬁcant difference between
treated and untreated cells (P< 0.05). It should be noted that
there were signiﬁcant differences between treated cells in the
presence and absence of S9 fraction (Table 1; P< 0.05).
4. Discussion
In the present study we found that HDZ inhibits the cell
growth of the CHO cells (Fig. 1). This ﬁnding is in good agree-
ment with previous report of Song and Zhang where they used
three cancer cell lines (Hela, CaSki, SiHa) and a normal cell
line (ECV304) [16].Table 1 Induction of chromatid breaks, polyploidy and mitotic inde
mix.
Treatment Aberrations per 100 meta
Chromatid breaks
Hydralazine (lg/ml)
0 – S9mix 4.7 ± 1.52a
20 – S9mix 16.3 ± 2.51a
40 – S9mix 35.0 ± 13.89b
Statistical analysis
F (df = 2, 6) 10.44
P-value 0.011
0 ± S9 mix 4.3 ± 0.57a
20 ± S9mix 4.6 ± 1.52a
40 ± S9mix 14.6 ± 3.21b
Statistical analysis
F (df = 2, 6) 23.87
P-value 0.001
Positive controls
Mitomycin-C (0.06 lg/ml) 19.0 ± 1.0
Sodium arsenite (1 lM) 20.0 ± 2.64
Note: The results are average of three independent experiments.
F, df, p same alphabets means no statistically signiﬁcant difference betweOur present ﬁndings demonstrated that HDZ (S9 mix)
induced the chromatid breaks. This ﬁnding also might be inter-
preted with the formation of free oxygen radicals by HDZ
which was previously reported [6,7]. It should be mentioned
that the present data are in agreement with previous studies
reporting the mutagenic effect of HDZ in bacterial test systems
[9–12].
Interestingly, the present results indicated that in cells trea-
ted with HDZ and presence of S9 mix compared with the cell
treated with HDZ without S9 fraction, the level of chromatid
breaks was reduced and level of mitotic index increased. This
ﬁnding might be explained by: (1) The S9 mix fraction has
many enzymes such as NAT (N-acetyl transferase). NAT
may acetylate HDZ and subsequently form two metabolites
(N-acetyl hydralazine and 3-methyl-triazolo-phthalazine).
These products may be less toxic than the original drug and
cause reduction in chromosome aberrations. (2) We know that
the S9 mix also contains catalase (an important antioxidant
enzyme). It has been shown that catalase detoxiﬁes the active
free radicals specially hydroxyl radicals [26]. These suggest that
HDZ metabolites are less toxic than the original drug. It
should be noted that same effect of S9 fraction was previously
reported in relation to HDZ [27] and other drugs such as pro-
pranolol [24].
In conclusion, HDZ can cause chromatid breaks in CHO
cells, and the metabolic activation system (S9 mix) plays an
important role in the drug cytotoxicity reduction. Some studies
have revealed plasma levels of HDZ vary among individuals
[28]. It has been reported that HDZ is subject to polymorphic
acetylation; slow acetylators generally have higher plasma level
of HDZ and require lower doses to maintain control of blood
pressure [29,30]. The U.S. Food and Drug Administration
(FDA; an agency responsible for the control and safety of food
and drugs) has established ﬁve categories (A–E) to indicate the
potential of a drug to cause birth defects if used during
pregnancy. The categories are determined by the reliabilityx in CHO cells by Hydralazine in the presence and absence of S9
phases Mitotic index (%)
Polyploidy
8.0 ± 1.0a 7.7 ± 0.52a
7.6 ± 0.57a 3.9 ± 0.62b
8.3 ± 4.04a 2.06 ± 0.64c
0.05 68.58
0.945 <0.001
6.6 ± 2.51a 7.6 ± 0.32a
5.3 ± 0.57a 5.7 ± 0.26b
6.6 ± 1.52a 5.08 ± 0.38b
0.59 50.53
0.582 <0.001
20.0 ± 3.60 3.4 ± 0.40
12.3 ± 2.51 3.7 ± 0.62
en groups (P> 0.05).
346 M. Sedigh-Ardekani, M. Saadatof documentation and the risk to beneﬁt ratio. HDZ has been
assigned to pregnancy category C by the FDA. The category C
means that animal reproduction studies have shown an
adverse effect on the fetus and there are no adequate and
well-controlled studies in humans, but potential beneﬁts may
warrant use of the drug in pregnant women despite potential
risks.
Finally it should be mentioned that HDZ must be used cau-
tiously in general and particularly in children and pregnant
women. HDZ should only be given during pregnancy when
beneﬁt outweighs risk. However, further experiments are nec-
essary to clarify the signiﬁcance of the present ﬁndings, partic-
ularly in humans with respect to genetic polymorphisms of the
genes involved in metabolism of HDZ.
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